0
0
Read Time:4 Minute, 37 Second
In recent years, with the rising prevalence of chronic and infectious diseases, the demand for real-time detection in clinical diagnostics and the need for highly sensitive, portable, and rapid immunoassay methods have been increasing. The combination of microfluidics and immunoassays is addressing many of the challenges faced by traditional immunoassays in research and clinical diagnosis. Microfluidic immunoassay technology miniaturizes the laboratory on a chip, eliminating the need for sample preparation steps, benchtop instruments, and trained professionals. Its portability increases the accessibility of this technology, especially in low-resource settings.
Download Sample Report Here @ https://www.meticulousresearch.com/download-sample-report/cp_id=5034
Multiplexed Panel Detection: A Growing Trend
A major trend in the microfluidic immunoassay market is the rise of multiplexed panel detection. In many cases, a single molecular event is insufficient to indicate the pathophysiology of complex diseases, such as cancer. Relying on a single molecular event as a biomarker for early detection may fail to comprehensively identify individuals with the disease. This has driven the need for multianalyte-based tests.
The adoption of multiplexed diagnostic testing has increased, offering benefits like reduced reagent consumption, multiple analyte detection, improved sensitivity, and shorter reaction times. Microfluidic technology enables precise spatial control in immobilizing proteins and biomolecules within microchannels, facilitating multiplexing and multiparameter assays. Consequently, the ability to detect multiple analytes in a single test is becoming a prominent trend.
Many companies are developing multi-analyte tests to expand their lab-on-chip (LOC) portfolios. Point-of-care (POC)-based multi-analyte testing for infectious diseases can be crucial for diagnosis and prompt treatment, as traditional lab culture-based analysis is time-consuming, and single-parametric tests may provide incomplete diagnoses. Delays in diagnosis can lead to septic shock and even death.
Browse in Depth @ https://www.meticulousresearch.com/product/microfluidic-immunoassay-market-5034
Microfluidic Immunoassays in Cardiology
Cardiology, which deals with heart-related diseases and disorders, has seen a rise in the use of microfluidic immunoassay. Heart disease has become increasingly prevalent, accounting for 17.1% of deaths in the U.S. Microfluidic immunoassays provide a technologically advanced alternative to traditional methods, offering rapid results in emergencies and expanding access to testing in low-resource environments. These assays detect biomarkers released in the blood after heart muscle injury, aiding in the diagnosis of cardiovascular diseases.
Key market players such as Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Micropoint Biotechnologies Co., Ltd. (China), and QuidelOrtho Corporation (U.S.) are offering microfluidic cartridges for the assessment of biomarkers like Troponin, creatine kinase (CK-MB), D-Dimer, CRP, and myoglobin.
Recent developments are focusing on introducing multiplexed microfluidic immunoassays to detect multiple cardiac conditions using limited samples in less time. Researchers also use these multiplexed panels to gain insights into disease mechanisms.
Microfluidic Immunoassay Market Insights
Recent analysis by Meticulous Research® projects the microfluidic immunoassay market to reach $1.59 billion by 2031, growing at a Compound Annual Growth Rate (CAGR) of 7.3% from 2024 to 2031. Innovation in research and development is advancing the market, improving patient outcomes and fostering trends such as miniaturization, automation, and multiplexed detection. The portability of detection systems and microfluidic cartridges, along with advancements in fabrication technologies, further bolster this market.
The North American region is expected to hold a substantial market share by 2024, driven by the presence of key players like Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), and QuidelOrtho Corporation (U.S.). These companies have established a strong presence, contributing to the widespread adoption of their products.
Conclusion
The microfluidic immunoassay market is on a promising growth trajectory, driven by the increasing use of immunoassays in drug discovery and biomarker detection, the advantages of lab-on-chip technology over conventional methods, and a growing focus on research and development by pharmaceutical and biotechnology companies. The rise in point-of-care diagnostics and recent technological advancements are expected to offer significant market growth opportunities in the years to come.
Buy Now@ https://www.meticulousresearch.com/Checkout/80588586
Microfluidic Immunoassay Market Research Summary
| Particulars | Details |
| Number of Pages | 259 |
| Format | |
| Forecast Period | 2024-2031 |
| Base Year | 2023 |
| CAGR | 7.3% |
| Estimated Market Size (Value) | $1.59 billion by 2031 |
| Segments Covered | By Product
By Technology
By Application
By End User
|
| Countries Covered | North America (U.S. and Canada), Europe (Germany, France, U.K., Italy, Spain, and Rest of Europe), Asia-Pacific (China, Japan, India, and Rest of Asia-Pacific), Latin America, and Middle East & Africa |
| Key Companies | The key players operating in the global microfluidic immunoassay market are Becton, Dickinson and Company (U.S.), Revvity, Inc. (U.S.), Abbott Laboratories (U.S.), Siemens Healthineers AG (Germany), Nanomix Corporation (U.S.), Micropoint Biotechnologies Co., Ltd. (China), Biosurfit SA (Portugal), Koninklijke Philips N.V. (Netherland), NanoEnTek Inc. (South Korea), and QuidelOrtho Corporation (U.S.). |
About Meticulous Research®
Meticulous Research® is a leading provider of comprehensive market intelligence, offering actionable insights and analysis across various industries. Our reports empower businesses to make informed decisions, drive growth, and remain competitive in a rapidly evolving marketplace.
Contact:
Meticulous Market Research Pvt. Ltd.
1267 Willis St, Ste 200 Redding,
California, 96001, U.S.
USA: +1-646-781-8004
Europe : +44-203-868-8738
APAC: +91 744-7780008
Email- sales@meticulousresearch.com
Visit Our Website: https://www.meticulousresearch.com/
Connect with us on LinkedIn- https://www.linkedin.com/company/meticulous-research
Happy
0 %
Sad
0 %
Excited
0 %
Sleepy
0 %
Angry
0 %
Surprise
0 %